However, further updated data from this research showed that the extension of OS in lung cancer patients treated with Nivolumab and Ipilimumab was not associated with TMB and PD-L1 (Hellmann, Paz-Ares & Caro, 2019). Here, CD274 is linked to lung carcinoma.